Addendum
Nivolumab (urothelial carcinoma, adjuvant) – Addendum to Project A25-154
Report documents
-
Addendum
Nivolumab (urothelial carcinoma, adjuvant) – Addendum to Project A25-154
Dossier assessment
Indication:
Adults with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1% and a high risk of recurrence after undergoing radical resection, for whom cisplatin-containing therapy is not suitable or who have already received neoadjuvant treatment with cisplatin; adjuvant treatment
Result of dossier assessment:
- Male patients: unchanged after addendum: hint of a minor added benefit
- Female patients: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
05-06-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-45
- Commission
- Commission awarded on 29.04.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-45_en
Connected Projects
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed